BRAF and melanoma: Of note, the activation of P300 also contributes to the resistance to BRAF-targeted therapy by activating ERK signal and mitochondrial oxidative phosphorylation,157,158 highlighting targeting P300 as a valuable synergistic therapeutic approach to sensitize melanoma cells toward MAPK pathway inhibition.